A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT07200128
Status
Completed

Conditions

  • Severe Alopecia Areata

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.

Key Dates

Start date
Feb 3, 2025
Status verified
Jun 2026
Primary completion
May 30, 2025
Completion
May 30, 2025

Study Design

Enrollment
123 participants (actual)

Arms

  • Arm: Patients with severe Alopecia Areata

Primary Outcome Measure

% of patients for whom their clinician was "satisfied" with current control of alopecia areata [ Time Frame: 11/15/2023 to 06/10/2024 ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10001-

Find similar trials in New York, NY

By research site
Pfizer· New York, NY

Related Studies